One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Levatinib mesylate is a synthetic oral vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase inhibitor with potential anti-tumor activity. E7080 blocks the activation of VEGFR2 through VEGF, thereby inhibiting the VEGF receptor signaling pathway, reducing the migration and proliferation of endothelial cells, as well as endothelial cell apoptosis.
One year of qualification
Audited Supplier
Pharma Sources Insight January 2025
![8-(BroMoMethyl)-1,4-dioxaspiro[4.5]decane](https://eimg.pharmasources.com/image/product/20231204/63cf398ce46b9eff22908d55582c5466jpg!145)
